This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

SKYCellflu Quadrivalent

SK Chemicals Co., Ltd.

Description: SKYCellflu Quadrivalent is an inactivated cell-culture derived influenza vaccine, produced via a sterile incubator using cell-culture technique and characterized by its antibiotic- and preservative-free quality. This quadrivalent influenza vaccine protects against four virus types, two subtypes of type-B viruses (Yamagata and Victoria) and two subtypes of type-A viruses (H1N1 and H3N2).

Deal Structure: SK Chemicals and JW Shinyak
In July 2016, SK Chemicals announced a joint marketing agreement with JW Shinyak for the cell-culture influenza vaccine SKYCellflu Quadrivalent. With this agreement, SK Chemicals and JW Shinyak will conduct sales and marketing activities for SKYCellflu Quadrivalent at hospitals and specialized clinics (dermatology, urology, plastic surgery, etc.), respectively, beginning this autumn.


SKYCellflu Quadrivalent News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug